Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Promising drug duo targets Hard-to-Treat HER2 cancers

NCT ID NCT04585958

First seen Nov 01, 2025 · Last updated Apr 30, 2026 · Updated 31 times

Summary

This early-phase study tests two drugs—DS-8201a and olaparib—together in people with advanced HER2-positive cancers that have spread or can't be removed. The goal is to find the safest dose and see if the combination can shrink or stabilize tumors. About 55 adults with certain solid tumors or platinum-resistant ovarian cancer will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC MALIGNANT SOLID NEOPLASM are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Dana-Farber Cancer Institute

    RECRUITING

    Boston, Massachusetts, 02215, United States

    Contact

    Contact Phone: •••-•••-••••

  • Mayo Clinic Hospital in Arizona

    ACTIVE_NOT_RECRUITING

    Phoenix, Arizona, 85054, United States

  • Mayo Clinic in Florida

    RECRUITING

    Jacksonville, Florida, 32224-9980, United States

    Contact

    Contact Phone: •••-•••-••••

  • Mayo Clinic in Rochester

    RECRUITING

    Rochester, Minnesota, 55905, United States

    Contact

    Contact Phone: •••-•••-••••

  • University of Pittsburgh Cancer Institute (UPCI)

    RECRUITING

    Pittsburgh, Pennsylvania, 15232, United States

    Contact

    Contact Phone: •••-•••-••••

Conditions

Explore the condition pages connected to this study.